arrow
T

Thomas John

Peter MacCallum Cancer Centre
H指数:66
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment and Survival Outcomes for Indigenous and Non-Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross-Sectional Cohort Study

维多利亚肺癌登记处中土著和非土著澳大利亚人的治疗与生存结局:一项回顾性横断面队列研究

2026-07-290
OAAI
EP.17.02 Treatment and Survival Outcomes for Indigenous Australians Within the Victorian Lung Cancer Registry

EP.17.02 维多利亚肺癌登记系统中的原住民澳大利亚人治疗与生存结局

2025-10-230
PRE
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC An Open-Label Phase 2 Trial (ILLUMINATE)

Durvalumab,Tremelimumab和铂类化疗在EGFR突变阳性NSCLC中的应用开放标签2期试验 (illumate)

2025-02-010
OA
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

在CheckMate 9LA随机试验中,转移性非小细胞肺癌患者一线nivolumab联合ipilimumab进行2周期化疗与单独4周期化疗的五年结果

2024-11-012
OAAI
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

ALKTERNATE: 一项在ALK阳性NSCLC中交替使用氯拉替尼和克唑替尼的初步研究

2024-09-010
OA
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

研究总结: 奥希替尼治疗EGFR突变非小细胞肺癌的总生存期

2024-03-110
OAAI
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

奥希替尼和吉非替尼交替治疗晚期EGFR-T790M阳性非小细胞肺癌的II期试验: 振荡

2024-02-286
OAAI
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

CheckMate 9LA随机试验中一线nivolumab加伊匹单抗联合化疗治疗转移性非小细胞肺癌的四年临床更新和治疗转换调整结果

2024-02-1221
OAAI
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer : Preliminary Results of the ImmunoPET Phase 0 Study

非小细胞肺癌患者的PD-L1正电子发射断层扫描成像: ImmunoPET 0期研究的初步结果

2023-11-017
PRE